185 related articles for article (PubMed ID: 31231012)
1. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
[TBL] [Abstract][Full Text] [Related]
2. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.
Lindgren M; Samuelsson J; Nilsson L; Knutsen H; Ghanima W; Westin J; Johansson PL; Andréasson B
Eur J Haematol; 2018 May; 100(5):419-425. PubMed ID: 29369421
[TBL] [Abstract][Full Text] [Related]
4. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
5. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
9. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Quintás-Cardama A; Kantarjian HM; Giles F; Verstovsek S
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):409-16. PubMed ID: 16810616
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
Lazzarino M; Vitale A; Morra E; Gagliardi A; Bernasconi P; Torromeo C; Inverardi D; Burgio V; Castello A; Bernasconi C
Br J Haematol; 1989 Jun; 72(2):173-7. PubMed ID: 2757963
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Löfvenberg E; Nordenson I; Wahlin A
Cancer Genet Cytogenet; 1990 Oct; 49(1):57-67. PubMed ID: 2397474
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.
Latagliata R; Spadea A; Cedrone M; Di Giandomenico J; De Muro M; Villivà N; Breccia M; Anaclerico B; Porrini R; Spirito F; Rago A; Avvisati G; Alimena G; Montanaro M; Andriani A;
Cancer; 2012 Jan; 118(2):404-9. PubMed ID: 21692060
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
[No Abstract] [Full Text] [Related]
15. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
[TBL] [Abstract][Full Text] [Related]
16. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Ahn IE; Natelson E; Rice L
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S300-4. PubMed ID: 24290215
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
[TBL] [Abstract][Full Text] [Related]
18. Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
Riley CH; Jensen MK; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM
Blood; 2011 Aug; 118(8):2170-3. PubMed ID: 21708889
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
20. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]